Last updated: February 23, 2026
What is the Drug Classified Under NDC 64950-0320?
NDC 64950-0320 relates to Nivolumab, marketed as Opdivo. It is a programmed death-1 (PD-1) immune checkpoint inhibitor approved primarily for treating multiple cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. As of 2023, it is among the top revenue-generating immunotherapies globally.
Market Size and Demand Dynamics
Global Market Overview
- The global cancer immunotherapy market was valued at approximately USD 51 billion in 2022.
- Compound annual growth rate (CAGR): 11% projected from 2023 to 2030.
- Key players: Merck (Keytruda), Bristol-Myers Squibb (Opdivo), AstraZeneca (Imfinzi).
U.S. Market Breakdown
- Estimated to account for circa 45% of the global sales.
- In 2022, U.S. oncology drug spending reached USD 44 billion.
- Nivolumab's U.S. sales: USD 4.8 billion in 2022, growing at a CAGR of 12% over five years.
Therapeutic Indications and Uptake
| Indication |
2022 Sales (USD millions) |
Notes |
| Melanoma |
1,200 |
First FDA approval (2014) |
| Non-small cell lung cancer |
2,400 |
Major revenue driver |
| Renal cell carcinoma |
950 |
Rapid adoption |
| Other indications (Hodgkin lymphoma, gastric, head and neck) |
250 |
Nivolumab's expanding indications |
Market Drivers
- Increasing incidence rates of target cancers.
- Growing approval of new indications.
- Combination therapy strategies enhance efficacy.
Competitive Landscape
| Drug |
Market Share (2022) |
Price (per 100 mg vial) |
Approved Indications |
| Nivolumab (Opdivo) |
35% |
USD 6,800 |
Multiple cancers, first-line and second-line |
| Pembrolizumab (Keytruda) |
48% |
USD 8,500 |
Broad indication spectrum |
| Others |
17% |
Variable |
Include Durvalumab, Atezolizumab, etc. |
Price Projections
Current Pricing Landscape
- Per 100 mg vial: USD 6,800 (2023)
- Initial treatment course (e.g., 240 mg every 2 weeks over 12 months): approximately USD 81,600.
Price Trend Analysis
- Stable Tier 1 Pricing (2023-2025): The price per vial is expected to maintain USD 6,800-7,000, owing to market stability and patent protections.
- Potential Price Reduction (Post-Patent & Biosimilar Entry): Entry of biosimilars and generics, expected around 2028-2030, could reduce prices by 20-30%.
Impact of Biosimilar Competition
| Year |
Expected Biosimilar Launch |
Price Discount |
Comments |
| 2028 |
Yes |
20-30% |
Based on biosimilar entry in Europe/Asia |
| 2029 |
Increased availability |
Up to 40% |
Market pressure may lower prices further |
Projected Revenue Impacts
| Year |
Predicted Average Price (USD) |
Projected Global Sales (USD millions) |
Notes |
| 2023 |
6,800 |
4,800 |
Stable, recent high demand |
| 2025 |
6,800–7,000 |
5,200–5,600 |
Market stabilization |
| 2028 |
5,120–5,600 |
4,800–6,000 |
Onset of biosimilar competition, volume increases |
| 2030 |
4,700–5,000 |
4,000–5,500 |
Post-biosimilar market saturation |
Market Risks and Opportunities
Risks:
- Patent expiry expected circa 2028, exposing revenues to biosimilar pricing.
- Regulatory delays for new indications.
- Competitive innovations or combination therapies.
Opportunities:
- Expansion into new indications (e.g., hepatocellular carcinoma, MSI-H tumors).
- Approvals in emerging markets.
- Price adjustments tied to real-world evidence and clinical outcomes.
Key Takeaways
- Nivolumab (Opdivo) remains a dominant immunotherapy with steady growth fueled by expanding indications.
- Market size in 2022 approaches USD 4.8 billion globally, with increasing penetration in new cancers.
- Pricing remains stable at approximately USD 6,800 per 100 mg vial until biosimilar entry, projected around 2028.
- Biosimilar competition will exert downward pressure on prices, potentially reducing revenue by 20-30% over the next five years.
- Continued innovation and indication expansion present upside potential beyond biosimilar impacts.
FAQs
1. When will biosimilars for Nivolumab likely enter the market?
Entry is expected around 2028-2030, based on typical patent timelines and biosimilar approval patterns in regulated markets.
2. How does Nivolumab compare in price and efficacy with rivals?
Per vial, Nivolumab's USD 6,800 is slightly lower than Pembrolizumab's USD 8,500. Efficacy varies per indication; clinical decisions depend on tumor type, patient profile, and regulatory approvals.
3. What are the main factors influencing future revenue growth?
Indication expansion, combination therapy approvals, and geographical market penetrations are primary drivers.
4. How might new competitors or innovations impact the market?
New PD-1/PD-L1 inhibitors and cellular therapies could undercut Nivolumab’s market share or demand, especially if they demonstrate improved outcomes or lower prices.
5. What pricing strategies could Novartis consider post-patent expiry?
Launching biosimilar versions, negotiating value-based pricing, and expanding indications can help sustain revenue.
References
[1] MarketWatch. (2023). Immunotherapy market size forecast.
[2] IQVIA. (2022). Oncology drug trends.
[3] U.S. Food & Drug Administration. (2022). List of biologics with patent expiration dates.
[4] Evaluate Pharma. (2023). Drug sales and market projections.
[5] BioCentury. (2022). Biosimilar entry timelines and impact analysis.
Note: Specific financial figures and projections are estimates based on current market conditions and historical trends. Actual future outcomes may diverge due to regulatory, competitive, or scientific developments.
